XSPA XpresSpa Group Inc

XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced the opening of Treat™’s first brick and mortar location in Terminal 4 at John F. Kennedy International Airport. Just in time for the holiday travel rush, Treat will be a fully operational upscale health and wellness center with access to on-site care with medical professionals, Covid-19 rapid PCR tests, IV drip infusion therapy, flu shots and on-site virtual sessions like yoga and fitness and feature a bespoke collection of retail partners including Bala, p.Volve, Noshinku, LARQ, Hilma, Memobottle and Ostrchpillow.

“In this pandemic world, people are now prioritizing health and wellness, especially when traveling,” said Doug Satzman, XpresSpa Group CEO. “This first-of-it’s-kind suite of travel health and wellness services is leading a new era in wellness travel - whether you need a test, want to work out, seek healthcare on-the-go, or just escape from the stressors of travel, Treat will be an invaluable set of resources as traveler needs continue to evolve.”

Satzman continued, “Treat’s membership, via the mobile app, provides unlimited access to on-demand virtual care and provides a health wallet, where one can upload, store and control medical records in a HIPPA-secure environment. Use the app to schedule appointments at Treat in-airport wellness centers starting at JFK T4 today for everything from Covid-19 Rapid PCR testing and anxiety care to reserving private rooms for yoga or meditation sessions. In conjunction with the website, Treat.com provides the latest COVID travel requirements, delivers original content, tips and offers a variety of products that make traveling the world with confidence easier.”

“We are very pleased to partner with XpresSpa and the Port Authority to launch Treat’s first brick and mortar location,” said Roel Huinink, President and CEO of JFKIAT, the operator of Terminal 4 at John F. Kennedy International Airport. “As we enter the holiday season and continue to experience increases in air travel, ensuring a safe environment remains our highest priority. This partnership is our latest initiative to provide our customers with a safe and seamless experience, and we are very pleased that T4 will be the home of Treat’s first location.”

The launch of Treat’s first brick and mortar location (Phase Three) is the final major milestone in the three-phase plan to provide travelers with integrated health and wellness care at the tip of their fingers through Treat. Combined with the June launch of treat.com (Phase One) and, Treat’s mobile app (Phase Two) launched in August, Treat’s first physical location, rounds out a 360 degree offering for members and travelers.

About XpresSpa Group, Inc.

XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company operating three distinct brands: Treat™, XpresCheck™, and XpresSpa™. Treat is a travel health and wellness brand that will be providing on-demand access to healthcare through technology and personalized services. XpresCheck is a leading on-site airport provider of COVID-19 screening and testing with 13 locations in 11 domestic airports. XpresSpa is a leading airport retailer of spa services and related health and wellness products, with 43 locations in 21 airports globally. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com.

To learn more about Treat, visit: www.Treat.com.

To learn more about XpresCheck, visit: www.XpresCheck.com.

To learn more about XpresSpa, visit: www.XpresSpa.com.

Twitter: @Treat_Care and Instagram: @treat_care

Twitter: @xprescheck and Instagram: @realxprescheck

Twitter @XpresSpa and Instagram: @XpresSpa

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability to further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters, and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Media:

JFPRMEDIAGROUPJulie FergusonJulie@jfprmedia.com(312) 385-0098

Investor Relations:

ICRRaphael Grossir@xpresspagroup.com(203) 682-8253

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/43e8c545-504a-48b2-a8cb-39f23d9d121a